Navigation Links
Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
Date:7/14/2008

PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 10th Biennial FASEB Summer Research Conference Protein Phosphatases in Snowmass Village, Colorado. The poster presentation entitled, "Trodusquemine (MSI-1436), An Allosteric Inhibitor of Protein Tyrosine Phosphatase 1B," concluded that MSI-1436 is a selective, reversible and noncompetitive inhibitor of PTP-1B that enhances insulin signaling through potent PTP-1B inhibition both in vivo and in vitro.

"The search to discover PTP-1B inhibitors as a therapeutic target for the treatment of obesity and type 2 diabetes has long been a goal of drug development but achieving the selectivity necessary to demonstrate safety has been a significant hurdle. The new information on the mechanism by which MSI-1436 inhibits PTP-1B supports its first-in-class status," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "MSI-1436 is the only reversible, noncompetitive inhibitor of PTP-1B in clinical stage development. It is the allosteric nature of MSI-1436 and its ability to reversibly inhibit PTP-1B that is believed to be the key to the safety we have observed in Phase 1. We anticipate this will be attractive to both potential partners and clinicians as we obtain further evidence of the efficacy and safety of MSI-1436 in future studies."

Inhibition of PTP-1B, a non-receptor isoform of the protein tyrosine phosphatase family, by MSI-1436 has been shown to reduce food intake, induce weight loss, and increase insulin sensitivity
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
2. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The ... in Boston, MA on May 29, ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may access Mr. ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... KNOXVILLE, Tenn. , May 23, 2013 /PRNewswire/ ... of 24-hour nurse triage and nurse advice lines, ... 10-person committee, comprising physician, nursing and administrative leaders, ... providing safe, quality and cost-effective services for hospital ... "As our national healthcare system evolves, it,s imperative ...
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... , , , , ... , THE WOODLANDS, Texas, July 21 ... biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, ... for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for ...
... , TOKYO, July 21 R-Tech Ueno, Ltd. ... on the new compound RK-023 that is being developed by our ... see the note below) has been completed. , ... of a patch test (open, closed, photo-patch test), single-dose study and ...
Cached Medicine Technology:Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 2Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 3Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 4R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
(Date:5/23/2013)... (PRWEB) May 24, 2013 On March 14, ... nine women will hear in her lifetime: she had breast ... My Journey After a Breast Cancer Diagnosis ” (published by ... followed. , Rideout drew from her daily journals to give ... through surgery, chemotherapy and radiation treatments to deal with stage ...
(Date:5/23/2013)... Vegas Hotel Escapes, the premier Las ... new vacation packages for the upcoming memorial day ... for this patriotic holiday will be pleased to ... new special pricing available on VegasHotelEscapes.com's website. , ... the lowest prices possible on vacation packages to ...
(Date:5/23/2013)... May 23, 2013 Dr. Damon Huffman of ... suffer from gum disease a revolutionary new treatment method with ... millions of Americans who suffer from periodontal disease, and many ... treatment. Dr. Huffman is hoping that LANAP will encourage ... treatment. , Periodontal disease can cause gums ...
(Date:5/23/2013)... City, Utah (PRWEB) May 23, 2013 ... the employer mandate . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... health care reform, a common question from employees is ... to Zane Benefits’ website, not necessarily. The health care ...
(Date:5/23/2013)... Winter Park, FL (PRWEB) May 23, 2013 ... 7 Day Belly Blast Diet to determine what makes ... diets. , The published review highlights three main components ... metabolic rate; achieving a positive mindset and the personal ... change calorie intake every 7 days to keep the ...
Breaking Medicine News(10 mins):Health News:Kimberley Rideout Shares Her Triumphant Cancer Survival Story 2Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2
... ... management client since 1983, and Sturgis Hospital (Sturgis, Mich.), a management client since ... , ... Brentwood, Tenn. (PRWEB) December 17, 2009 -- Quorum Health Resources hospital clients Rutherford ...
... ... Open to primary care doctors who agree to BCBSNC’s standard contract. Physicians may qualify ... ... -- Blue Cross and Blue Shield of North Carolina (BCBSNC) is leading ...
... , VIRGINIA BEACH, Va., Dec. 17, ... 12 Hampton Roads-area non-profit organizations at its first ,Breakfast ... mistress of ceremonies was local television personality, Barbara Ciara, ... breakfast keynote speaker was world-renowned ,champion, and four-time heavyweight ...
... , MIAMI, Dec. 17 Physicians ... today announced that it has issued its financial statements ... are being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a ...
... glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) ... developing cancer. The results regarding the association between GSTM1 ... or CRC were contradictory. However, the majority of previous ... the association of the GSTM1/GSTT1 null genotype with the ...
... data, the molecular mechanism of infection employed by Salmonella ... the HZI research group "Cytoskeleton Dynamics". The group,s results have ... journal " Cellular Microbiology ". Salmonella are ... absence of oxygen and thus propagate in the gut. The ...
Cached Medicine News:Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 3Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 2Health News:The Amerigroup Foundation 'Breakfast of Champions' Honors Community Leaders with Boxing Champion Evander Holyfield 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Invasion without a stir 2
Arthroscopic instrument system for instability and SLAP fixation....
The Charlotte Shoulder™ System address arthroscopic, mini-open and open procedures with time saving instrumentation....
Arthroscopic instrument system for instability and SLAP fixation....
Suture Cutter, straight...
Medicine Products: